<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997187</url>
  </required_header>
  <id_info>
    <org_study_id>02-2021-008</org_study_id>
    <nct_id>NCT04997187</nct_id>
  </id_info>
  <brief_title>Effect of Bacillus Coagulans in Adults With With Functional Constipation</brief_title>
  <official_title>Effect of Bacillus Coagulans on Various Symptoms and Fecal Microbial Diversity in Adults With With Functional Constipation: a Randomized, Double-blinded, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Yangsan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Yangsan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct a randomized, double-blind, placebo-controlled study to investigate&#xD;
      the effects of Bacillus coagulans on various symptoms and fecal microbial diversity in adults&#xD;
      with with functional constipation for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous study has indicated that Bacillus coagulans provided control of abdominal pain,&#xD;
      less discomfort during defecation, and a more normalized defecation style, especially in&#xD;
      adults with with functional constipation. Therefore, the investigators conduct a randomized,&#xD;
      double-blind, placebo-controlled study to investigate the effects of Bacillus coagulans&#xD;
      various symptoms and fecal microbial diversity in adults with with functional constipation&#xD;
      for 8 weeks; the safety of the compound are also evaluated. The Investigators examine&#xD;
      constipation visual analogue scale, Bristol Stool Form Scale type 3 &amp; 4 ratio, visual&#xD;
      analogue scale for irritable bowel syndrome (VAS-IBS) questionnaire score, IBS-symptom&#xD;
      severity scale, IBS quality-of-life questionnaire score, fecal microbial diversity at&#xD;
      baseline, as well as after 8 weeks of intervention. Eighty adults were administered either&#xD;
      400 mg of Bacillus coagulans or a placebo each day for 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>constipation visual analogue scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>using visual analogue scale (100 mm). The minimum value was 0 mm and the maximum value was 100 mm, and higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bristol Stool Form Scale (BSFS) type 3 &amp; 4 ratio (%)</measure>
    <time_frame>8 weeks</time_frame>
    <description>using Bristol Stool Form Scale. The minimum value was 0% and the maximum value was 100%, and higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual analogue scale for irritable bowel syndrome</measure>
    <time_frame>8 weeks</time_frame>
    <description>using visual analogue scale (100 mm). The minimum value was 0 mm and the maximum value was 100 mm, and higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>irritable bowel syndrome-symptom severity scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>using IBS-Symptom Severity Scale questionnaire. The minimum value was 0 score and the maximum value was 500 score and higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>irritable bowel syndrome-quality-of-life</measure>
    <time_frame>8 weeks</time_frame>
    <description>using IBS-QOL questionnaire. The minimum value was 0 score and the maximum value was 5 score and higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal microbial diversity</measure>
    <time_frame>8 weeks</time_frame>
    <description>using gut microbiome analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Constipation - Functional</condition>
  <arm_group>
    <arm_group_label>Bacillus coagulans group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group takes Bacillus coagulans for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group takes placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bacillus coagulans group</intervention_name>
    <description>Bacillus coagulans 400 mg/day for 12 weeks</description>
    <arm_group_label>Bacillus coagulans group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>Placebo 400 mg/day for 12 weeks</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - function constipation by Romes criteria IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal liver or renal function (more than twice the normal upper limit of the&#xD;
             research institute)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (&gt;160 mg/dL of fasting blood sugar)&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100 mmHg)&#xD;
&#xD;
          -  Uncontrolled thyroid diseases.&#xD;
&#xD;
          -  History of serious cerebro-cardiovascular diseases or cancer such as angina or&#xD;
             myocardial infarction within 6 months&#xD;
&#xD;
          -  History of structural abnormalities of colon within 4 year&#xD;
&#xD;
          -  History of medication for probiotics and psychiatric diseases such as severe&#xD;
             depression, schizophrenia, drug intoxication.&#xD;
&#xD;
          -  Alcohol abuser&#xD;
&#xD;
          -  Allergic reaction to this test food&#xD;
&#xD;
          -  Those who participated in other drug clinical trials within 1 month from the screening&#xD;
             date.&#xD;
&#xD;
          -  Severe gastrointestinal symptoms such as heartburn and indigestion&#xD;
&#xD;
          -  Those who are pregnant, lactating, or plan to become pregnant during the clinical&#xD;
             trial&#xD;
&#xD;
          -  Those who are judged to be unsuitable by the PI for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Yeoup Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yangsan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Yeoup Lee, MD, PhD</last_name>
    <phone>01091345959</phone>
    <phone_ext>055</phone_ext>
    <email>saylee@pnu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang Yeoup Lee</last_name>
    <phone>360-2860</phone>
    <phone_ext>055</phone_ext>
    <email>saylee@pnu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Gyeungsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Yeoup Lee, MD</last_name>
      <phone>360-1442</phone>
      <phone_ext>055</phone_ext>
      <email>saylee@pnu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ye Li Lee</last_name>
      <phone>360-2860</phone>
      <phone_ext>055</phone_ext>
      <email>saylee@pnu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>October 23, 2021</last_update_submitted>
  <last_update_submitted_qc>October 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Yangsan Hospital</investigator_affiliation>
    <investigator_full_name>Sang Yeoup Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

